MediView has announced the first patient enrolment in a multi-centre study to assess the procedural efficiency of its XR90 holographic surgical navigation system for soft tissue biopsy.
Titled “Clinical Evaluation of an Intra-procedural 3D Needle Guidance Platform for Performing Percutaneous Soft Tissue Tumor Biopsy as an Adjunct to Standard Image Guidance,” the study has received Institutional Review Board (IRB) approval.
The company noted that the study is being carried out at New York-Presbyterian/Weill Cornell Medical Center, Weill Cornell Medicine, MedStar Georgetown University Hospital, and MedStar Washington Hospital Center, aiming to enrol 104 subjects for the next 24-month period.
The primary goal is to assess the XR90 system as an adjunct to conventional imaging techniques, including ultrasound and computed tomography (CT), against only standard-of-care imaging during percutaneous tumour biopsy procedures.
This clinical feasibility evaluation is said to further characterise and quantify the potential advantages and utility of the XR90 AR [augmented reality] imaging and guidance platform, which is cleared by the US Food and Drug Administration (FDA).
MediView CEO Mina Fahim said: “We’re pleased to collaborate with leading healthcare institutions on this important study.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Our goal is to empower proceduralists by providing tools that can enhance clinician workflow and patient care. We look forward to evaluating how the XR90 can simplify procedures and support interventional radiology practices.”
Based in Cleveland, US, the company is focused on progressing human health via its digital AR ecosystem.
The company noted that its AR visualisation platform is designed to enhance image-guided medical procedures by providing intuitive 3D X-ray visualisation, enabling remote partnership, and offering evidence-based data insights.
Last year, MediView XR reported trial outcomes demonstrating the clinical precision of its XR90 system.
In a previous collaboration, GE Healthcare worked with MediView XR to develop the OmnifyXR interventional suite system, integrating medical imaging with mixed-reality solutions.
